PFE - Pfizer Inc.
37.66 0.00 (0.00%)
After hours: 4:23PM EDT
| Previous Close | 37.65 |
| Open | 37.59 |
| Bid | 37.60 x 45100 |
| Ask | 37.73 x 2900 |
| Day's Range | 37.48 - 37.73 |
| 52 Week Range | 32.32 - 39.43 |
| Volume | 19,709,297 |
| Avg. Volume | 20,408,223 |
| Market Cap | 220.295B |
| Beta | 0.92 |
| PE Ratio (TTM) | 10.46 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.66%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | N/A |
Yahoo Finance Video•5 hours agoBusiness + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board
Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!
- MarketWatch•1 hour ago
Pfizer, Eli Lilly non-opioid pain drug nears finish line
A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.
- TheStreet.com•2 hours ago
5 Big Biotech Stories to Watch
President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.
Reuters•4 hours agoNovartis hints at 2018 outlook hike despite drug price freeze
Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.
- The Wall Street Journal•6 hours ago
[$$] Novartis Won't Raise U.S. Drug Prices This Year
Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.
- Reuters•8 hours ago
Pfizer-Lilly pain drug meets late-stage trial goals
The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.
- Reuters•8 hours ago
Pfizer-Lilly pain drug meets late-stage trial goals
An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.
- Benzinga•8 hours ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...
- Reuters•10 hours ago
Hikma raising injectable opioids output to help ease shortage at U.S. hospitals
London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.
- Reuters•10 hours ago
Novartis joins Pfizer in halting U.S. drug price hikes
Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.
- Bloomberg•14 hours ago
Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.
- Bloomberg•14 hours ago
Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.
- Zacks•yesterday
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
- Investopedia•yesterday
TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise
Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.
